

Clinical Trial Protocol

Iranian Registry of Clinical Trials

25 Jun 2026

Assessment the effect of hydroxychloroquine on the treatment of unexplained recurrent abortion in women referred to Arash hospital

Protocol summary

Summary

The aim of this study is to assess the effect of hydroxychloroquine on unexplained recurrent abortion. This clinical trial would be conducted as a prospective and double blind survey. Inclusion criteria is women with at least 2 unexplained recurrent abortion and exclusion criteria is women with lupus and underlying diseases. Our sample size is 60. After getting informed consent of participants, they will be randomly divided into two groups of intervention and control. After positive pregnancy test, the intervention group will receive 200 mg hydroxychloroquine 2 times a day up to the twentieth gestational week, and control group will receive placebo as the same way of intervention group. Patients would be monitored by sonography in 6-8, 11-13 and 18-22 of gestational weeks and outcomes of pregnancy and its complications will be assessed.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2015120910664N2**

Registration date: **2016-07-18, 1395/04/28**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2016-07-18, 1395/04/28

Registrant information

Name

Reihaneh Pirjani

Name of organization / entity

Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 7788 3288

Email address

pirjani@razi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Experimental Medicine Research Center of Tehran University of Medical Science

Expected recruitment start date

2016-06-21, 1395/04/01

Expected recruitment end date

2017-12-22, 1396/10/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Assessment the effect of hydroxychloroquine on the treatment of unexplained recurrent abortion in women referred to Arash hospital

Public title

Effect of hydroxychloroquine on recurrent abortion treatment

Purpose

Treatment

Inclusion/Exclusion criteria

inclusion criteria : women with more than 2 unexplained abortion
exclusion criteria: women with rheumatoid; lupus erythematosus; underlying and heart diseases; smoking; consumption of alcohol and supplement; radiation contact

Age

From **18 years** old to **45 years** old

Gender

Female

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 60

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tehran University of Medical Science

Street address

Tehran University of Medical Science, Qods Street, Keshavarz Boulevard

City

Tehran

Postal code

Approval date

2016-06-26, 1395/04/06

Ethics committee reference number

IR.TUMS.REC.1395.2743

Health conditions studied

1

Description of health condition studied

recurrent abortion

ICD-10 code

O03

ICD-10 code description

Spontaneous abortion

Primary outcomes

1

Description

spontaneous abortion

Timepoint

any time during study

Method of measurement

observational

Secondary outcomes

1

Description

Intrauterine death

Timepoint

after 20 weeks of gestation

Method of measurement

observational

2

Description

preeclampsia

Timepoint

all the duration of pregnancy

Method of measurement

clinical and laboratory examination

3

Description

low birth weight

Timepoint

after birth

Method of measurement

weighing

4

Description

preterm labor

Timepoint

before 37 th week of gestation

Method of measurement

observational

5

Description

congenital morphological abnormalities

Timepoint

after birth

Method of measurement

observational

Intervention groups

1

Description

intervention group: After confirming the positive pregnancy test, patients will receive tablet of 200 mg hydroxychloroquine twice a day up to the twentieth week of pregnancy. Sonography will be done in weeks of 6-8, 11-13 and 18-22 of pregnancy.

Category

Treatment - Drugs

2

Description

control group: After confirming the positive pregnancy test, patients will receive placebo twice a day up to the twentieth week of pregnancy. Sonography will be done in weeks of 6-8, 11-13 and 18-22 of pregnancy.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Arash women hospital

Full name of responsible person

Dr.Reihaneh Pirjani

Street address**City**

Tehran

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Experimental Medicine Research Center of Tehran
University of Medical Science, Vice chancellor for res

Full name of responsible person

Dr Masoud Younesian

Street address

Tehran University of Medical Science, Keshavarz
boulevard, Qods street,

City

Tehran

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Experimental Medicine Research Center of Tehran
University of Medical Science, Vice chancellor for res

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Arash Women 's Hospital, Tehran University of
Medical sciences

Full name of responsible person

Dr. Reihaneh Pirjani

Position

Associated professor

Other areas of specialty/work**Street address**

Arash women hospital, Rashid street, Tehranpars

City

Tehran

Postal code**Phone**

+98 21 7788 3196

Fax**Email**

pirjani@razi.tums.ac.ir

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tehran University of Medical Science, Arash women
hospital

Full name of responsible person

Dr.Reihaneh Pirjani

Position

associated professor

Other areas of specialty/work**Street address**

Arash women hospital, Rashid street, Resalat
highway, Tehranpars

City

Tehran

Postal code**Phone**

+98 21 7788 3196

Fax**Email**

pirjani@razi.tums.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Arash Women 's Hospital , Tehran University of
Medical sciences

Full name of responsible person

Dr. Reihaneh Pirjani

Position

Assistant professor

Other areas of specialty/work**Street address**

Arash Women 's Hospital, Rashid Ave, Resalat
Highway, Tehranparse

City

Tehran

Postal code**Phone**

00

Fax**Email**

Web page address

empty

Sharing plan

Informed Consent Form

empty

Deidentified Individual Participant Data Set (IPD)

Clinical Study Report

empty

empty

Study Protocol

Analytic Code

empty

empty

Data Dictionary

Statistical Analysis Plan

empty